ArticleiScience2026
Neuronal Igfbp2 deficiency in the prefrontal cortex impairs cognition through synaptic dysfunction in male mice.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin-like growth factor binding protein 2 (Igfbp2) is known to participate in brain development and synaptic regulation, but its specific contribution to prefrontal cortex (PFC)-dependent cognitive function remains unclear. Here, we demonstrate that neuronal Igfbp2 in the PFC plays a critical role in maintaining cognitive performance and synaptic integrity. Neuron-specific Igfbp2 knockdown impaired recognition and spatial memory without altering emotional or locomotor behaviors. Mechanistically, loss of Igfbp2 reduced dendritic spine density, downregulated synapsin-1 and PSD-95 expression, and weakened excitatory synaptic transmission. Remarkably, the local infusion of recombinant Igfbp2 protein restored synaptic architecture and rescued cognitive deficits. Together, these findings identify neuronal Igfbp2 as an essential regulator of PFC-dependent cognition and highlight its potential as a therapeutic target for cognitive dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.